Jennifer Weidman

Jennifer Weidman, PhD, RAC has extensive work experience in regulatory affairs. Jennifer is currently the Vice President of Global Regulatory Affairs at Liquidia Technologies. Prior to that, they worked as the Executive Director of Global Regulatory Affairs at Mallinckrodt Specialty Pharmaceuticals from 2017 to 2020. Before that, they held various roles at Mallinckrodt LLC, Specialty Pharmaceuticals, including Senior Director of SpecPharma Regulatory Affairs from 2014 to 2020 and Director of Regulatory Affairs for Branded Pharmaceuticals from 1959 to 2019. Jennifer also served as the VP of R&D at Cancer Advances Inc. from 2006 to 2010 and as an Analyst and Lead Scientific Advisor at BioVentures from 2004 to 2006. Jennifer began their career as a Regulatory Scientist at Cato Research Ltd from 2004 to 2006. Overall, Jennifer Weidman has a strong background in regulatory affairs, with experience in both the pharmaceutical and biotechnology industries.

Jennifer Weidman received their Doctor of Philosophy (Ph.D.) degree in Cancer Epigenetics from Duke University School of Medicine. Jennifer completed their studies from 2000 to 2004.